Aspira Pathlab & Diagnostics L is a Healthcare Services company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY25 |
|---|---|
| Revenue | 22 |
| EBITDA (ex other income) | 3 |
| margin % | 15.8 |
| Owners' profit | 0 |
| EPS, as reported (₹) | 1.97 |
| ROE % · ROCE % | 16.6 · 15.7 |
| Debt / equity (x) | 0.10 |
| Cash from operations | 2 |
| Capex | (0) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|
| Revenue | 5 | 6 | 5 | 6 | 5 |
| Profit before tax | (0) | 1 | 0 | 1 | 0 |
| Net profit | 0 | 1 | 0 | 1 | 0 |
| EPS (₹) | 0.10 | 0.96 | 0.30 | 0.66 | 0.41 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 31,794 | 45.7 | 12.51 | 37.0 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 15,456 | 82.4 | 16.15 | 43.1 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 12,088 | 25.0 | 7.93 | 28.9 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 8,797 | 32.3 | 15.01 | 32.1 | 27.8 | 33.2 | 10.9 | 33.9 |
| NEPHROCARE HEALTH SERV L | 7,678 | 79.3 | 6.88 | 30.4 | 6.9 | 8.6 | — | 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,794 | 18.4 | 1.83 | 9.0 | 10.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 7 Sept 2026 · Board meeting on Sept 12 to consider fund raising via equity | board shareholder meetings | low | — | — |
| 5 Sept 2026 · Promoter Jay Bhanushali acquires 623 shares via open market | ownership changes | low | — | — |
| 3 Sept 2026 · Promoter Jay Bhanushali buys 957 shares of Aspira Pathlab via open market | ownership changes | low | — | — |
| 1 Sept 2026 · AGM notice and Annual Report FY2025-26 weblink dispatched | compliance | minimal | — | — |
| 1 Sept 2026 · 53rd AGM notice and e-voting details published in newspapers | compliance | minimal | — | — |
| 31 Aug 2026 · Annual Report FY26 and 53rd AGM notice submitted to BSE | compliance | low | — | — |
| 31 Aug 2026 · Aspira Pathlab 53rd AGM Notice on Sept 25, 2026 | board shareholder meetings | low | — | — |
| 31 Aug 2026 · Aspira Pathlab announces 53rd AGM on Sept 25; book closure Sept 19-25 | board shareholder meetings | low | — | — |
| 28 Aug 2026 · Aspira Pathlab announces 53rd AGM on September 25, 2026 via video conferencing | compliance | minimal | — | — |
| 28 Aug 2026 · Promoter group member buys 332 shares of Aspira Pathlab | ownership changes | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 8.4 |
| — |
| 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,693 | 47.2 | 6.95 | 17.2 | 12.9 | 11.5 | — | 36.0 |
| 3B BLACKBIO DX LTD. | 1,217 | 20.3 | 3.67 | 14.3 | 18.1 | 22.5 | (8.9) | 52.6 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 40.8 | 23.2 | 19 of 29 | 36% |
| P/B | 8.0 | 2.3 | 21 of 24 | 13% |
| ROCE | 13.4 | 6.1 | 8 of 29 | 75% |
| ROE | 16.6 | 7.3 | 8 of 26 | 72% |
| Debt / Equity | 0.1 | 0.0 | 17 of 26 | 36% |
| EBITDA margin | 17.7 | 25.6 | 15 of 24 | 39% |
| Revenue growth | 13.2 | 20.8 | 18 of 25 | 29% |
| Profit growth | 794.9 | 22.0 | 1 of 25 | 100% |
| Market cap | 98 | 38 | 14 of 30 | 55% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
